NCT03916627 2026-04-06Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC in Adult PatientsRegeneron PharmaceuticalsPhase 2 Active not recruiting65 enrolled
NCT05864144 2025-08-15A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid TumorsSensei Biotherapeutics, Inc.Phase 1/2 Active not recruiting98 enrolled